Oxford Immunotec Global PLC, a diagnostics company, develops and commercializes proprietary tests for the management of immune-regulated conditions in the United States, Europe, Japan, and China. The company develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immunologically controlled diseases. Its solution includes SPOT.TB test, a single-cell based method for identifying latent tuberculosis infection. The company was founded in 2002 and is headquartered in Abingdon, the United Kingdom.
115D Innovation Drive
Abingdon, OX14 4RZ
Founded in 2002
Oxford Immunotec Global PLC Announces Availability of the T-SPOT.CMV Test in the United States
Mar 31 15
Oxford Immunotec Global PLC announced the availability in the United States of a new test that measures the strength of a patient's cellular immune response to cytomegalovirus (CMV). This T-SPOT(R).CMV test is available as a Laboratory Developed Test from the Company's CLIA-certified and CAP accredited service laboratory. T cell immunity against CMV is a factor in controlling viral latency and susceptibility to CMV disease. CMV can affect individuals with weaknesses in their T cell response and it is therefore an important and common cause of morbidity and mortality in solid organ and hematopoietic stem cell transplant recipients. The T-SPOT.CMV test measures the strength of T cell responses to CMV specific antigens. The T-SPOT.CMV test has the potential to assist clinicians with monitoring anti-viral prophylaxis and evaluating patients at risk from CMV disease. The T-SPOT.CMV test leverages Oxford Immunotec's proprietary T-SPOT technology platform. The new test will be performed at Oxford Diagnostic Laboratories in Memphis, TN, where validation was performed. The test results will be available to customers within two days of receipt of a whole blood sample. The T-SPOT.CMV test builds on Oxford Immunotec's capabilities in T cell measurement technology, and is the first in a series of planned new products intended to help transplant patients and physicians manage immune regulated conditions. The T-SPOT.CMV test is pending approval in California, New York and Florida.
Oxford Immunotec Global PLC Appoints Stephen M. Gansler as Senior Vice President and Global Head of Human Resources
Mar 17 15
Oxford Immunotec Global PLC announced that Stephen M. Gansler has joined the company as Senior Vice President and Global Head of Human Resources. Most recently, Mr. Gansler was Senior Vice President, Human Resources, for Millennium Pharmaceuticals.
Oxford Immunotec Global PLC Announces Unaudited Consolidated Earnings Results for the Fourth Quarter Full Year Ended December 31, 2014; Provides Revenue Guidance for First Quarter and Full Year of 2015
Mar 3 15
Oxford Immunotec Global PLC announced unaudited consolidated earnings results for the fourth quarter full year ended December 31, 2014. For the quarter, the company reported total revenue of $12,118,000 compared to $10,225,000 a year ago. Loss from operations was $6,723,000 compared to $2,148,000 a year ago. Loss before income taxes was $6,617,000 compared to $3,271,000 a year ago. Net loss was $6,692,000 compared to $3,328,000 a year ago. Basic and diluted net loss per share attributable to ordinary shareholders was $0.39 compared to $0.38 a year ago. LBITDA was $6,166,000 compared to $2,961,000 a year ago. Adjusted LBITDA was $5,426,000 compared to $1,712,000 a year ago.
For the full year, the company reported total revenue of $49,505,000 compared to $38,784,000 a year ago. Loss from operations was $21,861,000 compared to $7,351,000 a year ago. Loss before income taxes was $22,020,000 compared to $8,572,000 a year ago. Net loss was $22,174,000 compared to $8,664,000 a year ago. Basic and diluted net loss per share attributable to ordinary shareholders was $1.28 compared to $2.26 a year ago. LBITDA was $20,226,000 compared to $7,143,000 a year ago. Adjusted LBITDA was $17,664,000 compared to $6,008,000 a year ago.
For the full year of 2015, the company expected revenue will be in the range of $60 million and $65 million, representing 21%-31% year-over-year growth.
For the first quarter of 2015, the company expected revenue will be in the range of $13.2 million and $13.7 million.